A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Genentech logo

Genentech

Status and phase

Completed
Phase 1

Conditions

Solid Cancers

Treatments

Drug: GDC-0449

Study type

Interventional

Funder types

Industry

Identifiers

NCT00968981
SHH4610g

Details and patient eligibility

About

This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.

Enrollment

67 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Histologically documented, incurable, locally advanced or metastatic solid malignancy that has progressed after first-line and second-line therapy (if there is a second-line therapy that has been shown to provide clinical benefit); patients with basal cell carcinoma will be excluded from this study unless they do not qualify for another open GDC-0449 clinical trial
  • For patients with disease that is evaluable by physical examination only, diagnosis must also include biomarker confirmation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Documented negative pregnancy test for women of childbearing potential and agreement to use an effective form of contraception for the duration of the study
  • Adequate hematopoietic capacity
  • Adequate hepatic function
  • Adequate renal function
  • At least 3 weeks since last chemotherapy, investigational agent, radiation therapy, or major surgical procedure and recovery to pre-treatment baseline or stabilization of all treatment-related toxicities

Exclusion Criteria

  • Known, untreated central nervous system (CNS) malignancies or treated brain metastases that are not radiographically stable for ≥ 3 months
  • Active infection requiring intravenous (IV) antibiotics
  • Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with hepatitis
  • Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g., gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications
  • Pregnant or lactating
  • Treatment with excluded medications, including strong CYP450 inhibitors and inducers

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

67 participants in 3 patient groups

A
Experimental group
Treatment:
Drug: GDC-0449
B
Experimental group
Treatment:
Drug: GDC-0449
C
Experimental group
Treatment:
Drug: GDC-0449

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems